FDA touts new authority as ODAC hosts adcomm to review delayed confirmatory trials for accelerated approvals

The FDA’s Oncologic Drugs Advisory Committee will meet Thursday to look at two cancer drugs that first won accelerated approval in 2009 and 2014 but have failed to complete their confirmatory trials.

The two drugs are both indicated for relapsed or refractory peripheral T cell lymphoma (PTCL) and from Acrotech…
Click here to view original post